We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAEP
801
DELISTED
Cantor Equity Partners III
CAEP
| $1.05M | 0.01% |
+100,000
| New | +$1.05M |
|
802
Hasbro
HAS
$12.9B
| $1.05M | 0.01% |
14,230
+3,152
| +28% | +$199K |
|
803
Ingersoll Rand
IR
$34.1B
| $1.03M | 0.01% |
12,383
+4,354
| +54% | +$343K |
|
804
Oculis Holding
OCS
$718M
| $982K | 0.01% |
+50,568
| New | +$929K |
|
805
Norwegian Cruise Line
NCLH
$9.07B
| $979K | 0.01% |
48,270
+11,121
| +30% | +$199K |
|
806
Iovance Biotherapeutics
IOVA
$1.93B
| $976K | 0.01% |
567,680
+765
| +0.1% | +$1.9K |
|
807
Fractyl Health
GUTS
$107M
| $969K | 0.01% |
597,841
+80,920
| +16% | +$131K |
|
808
Tyra Biosciences
TYRA
$1.91B
| $958K | 0.01% |
100,108
| – | – |
|
809
Generac Holdings
GNRC
$11.9B
| $914K | ﹤0.01% |
6,383
+1,347
| +27% | +$164K |
|
810
MarketAxess Holdings
MKTX
$5.71B
| $905K | ﹤0.01% |
4,052
+867
| +27% | +$191K |
|
811
Molson Coors Class B
TAP
$7.86B
| $891K | ﹤0.01% |
18,534
+3,988
| +27% | +$220K |
|
812
Wynn Resorts
WYNN
$10.2B
| $891K | ﹤0.01% |
9,508
+1,940
| +26% | +$165K |
|
813
Surgery Partners
SGRY
$2.1B
| $882K | ﹤0.01% |
39,688
-485,712
| -92% | -$10.8M |
|
814
Cirrus Logic
CRUS
$6.42B
| $874K | ﹤0.01% |
8,383
+4,566
| +120% | +$447K |
|
815
Bio-Techne
TECH
$11.2B
| $871K | ﹤0.01% |
16,936
+3,580
| +27% | +$180K |
|
816
Lyell Immunopharma
LYEL
$315M
| $870K | ﹤0.01% |
+98,425
| New | +$897K |
|
|
CHYM
817
Chime Financial
CHYM
$9.24B
| $863K | ﹤0.01% |
+25,000
| New | +$824K |
|
818
ScottsMiracle-Gro
SMG
$3.97B
| $859K | ﹤0.01% |
13,030
-157,598
| -92% | -$9.11M |
|
819
Kura Oncology
KURA
$816M
| $841K | ﹤0.01% |
145,704
| – | – |
|
|
PARA
820
DELISTED
Paramount Global Class B
PARA
| $839K | ﹤0.01% |
65,013
-1,330,929
| -95% | -$15.6M |
|
821
Nkarta
NKTX
$154M
| $830K | ﹤0.01% |
500,166
| – | – |
|
822
AES
AES
$10.5B
| $809K | ﹤0.01% |
76,911
+16,839
| +28% | +$180K |
|
823
Franklin Resources
BEN
$17.9B
| $799K | ﹤0.01% |
33,497
+7,308
| +28% | +$151K |
|
824
Fate Therapeutics
FATE
$291M
| $798K | ﹤0.01% |
712,650
-711,517
| -50% | -$827K |
|
825
Albemarle
ALB
$14B
| $797K | ﹤0.01% |
+12,711
| New | +$752K |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.